论文部分内容阅读
医药行业是少数几个没有受到危机冲击的行业,虽然产品越来越多,技术成功率和新产品获得上市许可的速度却呈现下降趋势。新上市产品的第一年收入有所下降,成功地推出产品正变得困难,预期收益也日益下降——如何才能在保持长期稳定收益的同时平衡研发预算、优先安排潜力项目?
The pharmaceutical industry is one of the few industries that have not been hit by the crisis. Although the number of products is increasing, the rate of technological success and the rate at which new products are licensed for listing have shown a downward trend. Revenue from the first year of new listings has declined. Successfully launching products is becoming more difficult and expected revenue is declining. How can we balance our R & D budget and prioritize potential projects while maintaining long-term, stable returns?